Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fluticasone/Salmeterol vs Advair Diskus in Healthy Volunteers
NCT04564456Phase 1Completed
- Sponsor
- Respirent Pharmaceuticals Co. Ltd.
- Start
- Sep 2020
- Primary completion
- Oct 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluticasone propionate and salmeterol in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Respirent Pharmaceuticals Co. Ltd. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the last measurable concentration. Started Sep 2020; status: completed.
02
Drugs
fluticasone propionatesalmeterol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04564456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564456.